News & Views
Clinical practice
U.S. Food and Drug Administration (FDA)
FDA Grants Accelerated Approval to Retifanlimab-Dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma
On March 22, 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to retifanlimab-dlwr (Zynyz®) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
March 23, 2023
Trending Topics